dailyai.report

£150 million will fund a new AI hub in central London over the next decade. Boehringer Ingelheim aims to accelerate drug discovery through this expanded footprint. The investment targets high-compute research and machine learning integration. This move secures a strategic talent pipeline for the pharmaceutical giant within the UK's growing tech sector.